Comparing YD Bio (NASDAQ:YDES) & Arbutus Biopharma (NASDAQ:ABUS)

Arbutus Biopharma (NASDAQ:ABUS) and YD Bio (NASDAQ:YDES) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Insider and Institutional Ownership

43.8% of Arbutus Biopharma shares are held by institutional investors. 19.9% of Arbutus Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Arbutus Biopharma and YD Bio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	0	1	1	0	2.50
YD Bio	1	0	0	0	1.00

Arbutus Biopharma currently has a consensus price target of $5.00, suggesting a potential upside of 4.06%. Given Arbutus Biopharma’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Arbutus Biopharma is more favorable than YD Bio.

Earnings and Valuation

This table compares Arbutus Biopharma and YD Bio”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08 million	67.52	-$33.50 million	$0.79	6.08
YD Bio	N/A	N/A	N/A	N/A	N/A

YD Bio has lower revenue, but higher earnings than Arbutus Biopharma.

Profitability

This table compares Arbutus Biopharma and YD Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	84.22%	90.98%	82.34%
YD Bio	N/A	N/A	N/A

Summary

Arbutus Biopharma beats YD Bio on 9 of the 9 factors compared between the two stocks.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company’s research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients’ HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

About YD Bio

YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.